GALA GLOBAL INC. (OTCMKTS:GLAG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

GALA GLOBAL INC. (OTCMKTS:GLAG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

Story continues below

As of November 27, 2017, Mr. Timothy Madden stepped down as CEO of Gala Global Inc. (the “Company”) to focus full time on the expanding responsibilities as the CEO of Controlled Environment Genomics Inc., a majority owned subsidiary of Gala Global Inc.

As of November 27, 2017, Mr. Maqsood Rehman was appointed as Gala Global Inc.’s Chief Executive Officer.

In addition. Effective November 9, 2017, Mr. Joseph Earle was appointed Gala Global Inc.’s Chief Operation Officer.

The biography for Mr. Rehman is set forth below:

Dr. Maqsood Rehman, is currently CEO of Gala Global, Inc. (“GLAG”) where he was the COO since June 2017. Prior to GLAG, Dr. Rehman was the Global Soybean Breeding Leader for Dow Agrosciences at Indianapolis, Indiana for six years. Previously, he worked as a soybean breeder for Monsanto Company at Oxford, Indiana for five years. Dr. Rehman has Masters and PhD degrees in Plant Science from University of Idaho, U.S.A. and Post Doctorate from University of Missouri-Columbia, Missouri. Dr. Rehman also has a diversified scientific background with training, and 10 plus years of practical experience in plant breeding, quantitative and molecular genetics and cytogenetics and project management.

Dr. Rehman’s experience ranges from providing leadership to the breeding organization to developing breeding strategies and budgets needed to accomplish breeding goals. He fills in the gaps by bringing key stakeholders together and aligns breeding goals with global commercial needs through effective communication. Dr. Rehman is also an expert at developing teams and providing effective and transparent communication process to achieve deliverables.

The biography for Mr. Earle is set forth below:

Joseph Earle, for the past twenty two years has specialized in serving as an accounting and other senior officer in various technology start-ups. Mr. Earle specializes in capital formation, corporate operations and corporate accounting. These technologies include pharmaceuticals, renewal energy, medical device, applications software, Internet based trading, hardware and software engineering and electronics manufacturing.

Prior to corporate accounting and operations, Mr. Earle had over twenty years capital market experience specializing in institutional and corporate capital management as well as securities trading. Mr. Earle specialized in risk based capital requirements and portfolio management for banks and government entities.

Mr. Earle has a BS in Finance from the University of Illinois and is certified in a number of financial and accounting application software specialties.

ITEM 8.01 Other Events.

Gala Pharmaceuticals Inc., has acquired services of Mark Livingston

Mr. Livingston has operated a pharmaceutical manufacturing firm in San Diego, CA for over 9 years. Mr. Livingston provides leadership to Gala Pharmaceuticals Inc., and assist a focus on setting the strategic direction of the company and instilling a culture of quality and continuous improvement. He is experienced in operations, finance, strategic planning, start-up companies, company turnarounds, management information systems and planning for the succession of closely held businesses.

Gala Pharmaceuticals Inc., has acquired the services of Nayaz Ahmed, PH.D, RAC, CQA, Director of Analytical Services & Product Development

Dr. Ahmed is a pharmaceutical development scientist experienced in R&D, regulatory compliance and quality control. He creatively resolves CMC and outstanding quality issues with firm knowledge of operations related to pharmaceuticals, biologicals and medical devices. At Gala Pharmaceuticals Inc., Dr. Ahmed has been instrumental in developing comprehensive regulatory compliance systems, SOP’s, and cGMP guided research to support product development. He is consulting with Gala Pharmaceuticals Inc.’s quality control department to execute new and improved quality systems to meet current FDA, ICH and ISO regulations and standards.

Gala Pharmaceuticals Inc., has acquired the services of Arshad Chaudry, Director of QC, Microbiology and Validation

Mr. Chaudry is a senior scientist experienced in commercial and R&D pharmaceutical microbiology and quality system validations. He has over 25 years of experience as a microbiologist, andis a consultant to GPI’s management team. Mr. Chaudryhas extensive experience with regulatory agencies and will represented GPI inits FDA andISO inspections. Mr. Chaudrywill play a key role in managing GPI’s manufacturing operations and the implementation of the company’s environmental monitoring programs to maintain its cGMP compliance.

The Company anticipates the installation and operation of a state of the art analytical laboratory and genetic engineering facility in San Diego County in Q1-2018.

The Company is being the process to change its name to Gala Pharmaceuticals Inc..

Item 9.01 Exhibits

(b)


Gala Global Inc. Exhibit
EX-10.1 2 gala_ex1001.htm AMENDED EXECUTIVE AGREEMENT – REHMAN Exhibit 10.1   AMENDED EXECUTIVE AGREEMENT Between GALA GLOBAL,…
To view the full exhibit click here

About GALA GLOBAL INC. (OTCMKTS:GLAG)

Gala Global Inc. is involved in the Hemp and Cannabidiol (CBD) industry. The Company is focused on the development, research and commercialization of products derived from the Hemp and Cannabis Plant. The Company focuses on a CBD flavored thin-film strip. The film strip delivery system uses a dissolving film strip that is absorbed in the mouth. The Company is engaged in seeking acquisition candidates in this area of interest in the nutraceutical and pharmaceutical industries. The Company also intends to enter into the medical marijuana cultivation industry as approved in the United States and Canada to build legalized cultivation operations. The Company’s services include the development of cannabinoid-based health and wellness products; the development of medical grade compounds, and the licensing of testing, genetics, labeling and packaging, tracking, production and standardization methods for the medicinal herb industry. The Company is also involved in the sale of Vape Mods.

An ad to help with our costs